ARCT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Arcturus Therapeutics Holdings Inc (ARCT) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock is trading significantly below analysts' price targets, the company's recent financial performance is weak, technical indicators are bearish, and there are no strong positive catalysts or signals from Intellectia Proprietary Trading Signals. Given the lack of immediate positive momentum and the user's impatience for optimal entry points, holding off on this investment would be prudent.
The technical indicators for ARCT are bearish. The MACD histogram is negative and contracting, the RSI is neutral at 38.824, and moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). Key support is at 6.486, with resistance at 7.602. The stock is currently trading below the pivot level of 7.044.
Analyst ratings remain generally positive, with multiple Buy ratings and price targets significantly above the current trading price. The company's innovative RNA platform and its potential in rare disease programs are highlighted as strengths.
Additionally, there is no recent news or significant trading activity from hedge funds, insiders, or Congress to act as a catalyst.
In Q4 2025, revenue dropped by 68.39% YoY to $7.2M, net income fell to -$29.08M (down 3.09% YoY), and EPS declined to -1.03 (down 7.21% YoY). Gross margin remained stable at 100%. Overall, the financial performance shows significant weakness.
Analysts generally maintain a positive outlook on ARCT, with Buy ratings from firms like B. Riley, Canaccord, and Roth Capital, and price targets ranging from $8 to $25. However, some analysts have lowered their price targets recently due to execution concerns and adjustments to their models.
